Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefepime + sulbactam is a fixed-dose combination antibiotic consisting of cefepime, a fourth-generation cephalosporin, and sulbactam, a beta-lactamase inhibitor. Cefepime exerts its bactericidal activity by binding to and inhibiting penicillin-binding proteins (PBPs), which are essential for the synthesis of the bacterial cell wall. Sulbactam acts as a suicide inhibitor of certain beta-lactamases (primarily Class A and some Class C enzymes), thereby protecting cefepime from enzymatic degradation and extending its spectrum of activity against resistant Gram-negative pathogens, including *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. This combination is typically administered parenterally for the treatment of serious systemic infections, particularly those suspected to be caused by multi-drug resistant (MDR) bacteria producing beta-lactamases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefepime + sulbactam.